These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 3133756)

  • 1. Does monotherapy of pulmonary infections in cystic fibrosis lead to early development of resistant strains of Pseudomonas aeruginosa?
    Watkins J; Francis J; Kuzemko JA
    Scand J Gastroenterol Suppl; 1988; 143():81-5. PubMed ID: 3133756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
    Dalzell AM; Sunderland D; Hart CA; Heaf DP
    Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study.
    Master V; Roberts GW; Coulthard KP; Baghurst PA; Martin A; Roberts ME; Onishko CR; Martin AJ; Linke RJ; Holmes M; Jarvinen A; Kennedy D; Colebatch KA; Hansman D; Parsons DW
    Pediatr Pulmonol; 2001 May; 31(5):367-76. PubMed ID: 11340683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
    Mastella G; Agostini M; Barlocco G; Bonomi U; Borgo G; Bozzino L; Cabrini G; Cappelletti LM; Castellani L; Conforti M
    J Antimicrob Chemother; 1983 Jul; 12 Suppl A():297-311. PubMed ID: 6311788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis.
    Gold R; Overmeyer A; Knie B; Fleming PC; Levison H
    Pediatr Infect Dis; 1985; 4(2):172-7. PubMed ID: 3885181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibiotic therapy of cystic fibrosis in children].
    Kapranov NI; Shabalova LA; Kashirskaia NIu; SimonovaO OI; Voronkova AIu; Osipova IA; Semykin SIu; Polikarpova SV; Postnikov SS
    Antibiot Khimioter; 2001; 46(2):26-32. PubMed ID: 11544748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
    Allen JE; Bosso JA; Saxon BA; Matsen JM
    Diagn Microbiol Infect Dis; 1987 Sep; 8(1):51-5. PubMed ID: 3126018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of aztreonam and ceftazidime in the treatment of respiratory infections in adults with cystic fibrosis.
    Salh B; Bilton D; Dodd M; Abbot J; Webb K
    Scand J Infect Dis; 1992; 24(2):215-8. PubMed ID: 1641599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
    Padoan R; Cambisano W; Costantini D; Crossignani RM; Danza ML; Trezzi G; Giunta A
    Pediatr Infect Dis J; 1987 Jul; 6(7):648-53. PubMed ID: 3302917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular epidemiological analysis of Pseudomonas aeruginosa strains causing failure of antibiotic therapy in cystic fibrosis patients.
    Bingen E; Denamur E; Picard B; Goullet P; Lambert-Zechovsky N; Foucaud P; Navarro J; Elion J
    Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):432-7. PubMed ID: 1358612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of ceftriaxone-resistant strains of Pseudomonas aeruginosa in cystic fibrosis patients.
    Paull A; Morgan JR
    J Antimicrob Chemother; 1986 Nov; 18(5):635-9. PubMed ID: 3100487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of Pseudomonas aeruginosa persistence during treatment with broad-spectrum cephalosporins of lung infections in patients with cystic fibrosis.
    Schryvers AB; Ogunariwo J; Chamberland S; Godfrey AJ; Rabin HR; Bryan LE
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1438-9. PubMed ID: 3118800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics.
    Vinks AA; Brimicombe RW; Heijerman HG; Bakker W
    J Antimicrob Chemother; 1997 Jul; 40(1):125-33. PubMed ID: 9249216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized double-blind evaluation of ceftazidime dose ranging in hospitalized patients with cystic fibrosis.
    Reed MD; Stern RC; O'Brien CA; Crenshaw DA; Blumer JL
    Antimicrob Agents Chemother; 1987 May; 31(5):698-702. PubMed ID: 3111360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis.
    Fluge G; Digranes A; Michalsen H; Stiris T; Bergan T; Qvigstad EK
    Eur J Respir Dis; 1987 Oct; 71(4):239-43. PubMed ID: 3319661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
    Waters V; Ratjen F
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Tolerance and efficacy of ceftazidime in combination with aztreonam for exacerbations of cystic fibrosis].
    Prévotat A; Leroy S; Perez T; Wallet F; Wallaert B
    Rev Mal Respir; 2010 May; 27(5):449-56. PubMed ID: 20569877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bacteriological effects of anti-Pseudomonas aeruginosa chemotherapy in cystic fibrosis.
    Bauernfeind A; Emminger G; Hörl G; Ott S; Przyklenk B; Weisslein-Pfister C
    Infection; 1987; 15(5):403-6. PubMed ID: 3121519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.